What's new
- Human medicines European public assessment report (EPAR): Avtozma, tocilizumab, Date of authorisation: 14/02/2025, Status: Authorised
- Human medicines European public assessment report (EPAR): Rivastigmine Sandoz, rivastigmine, Date of authorisation: 10/12/2009, Revision: 18, Status: Authorised
- Human medicines European public assessment report (EPAR): Rivastigmine Hexal, rivastigmine, Date of authorisation: 11/12/2009, Revision: 19, Status: Authorised
- Human medicines European public assessment report (EPAR): Rivastigmine 1 A Pharma, rivastigmine, Date of authorisation: 11/12/2009, Revision: 19, Status: Authorised
- Orphan designation: bexmarilimab Treatment of myelodysplastic syndromes, 25/03/2025 Positive
- Human medicines European public assessment report (EPAR): Sitagliptin / Metformin hydrochloride Mylan, sitagliptin hydrochloride monohydrate,metformin hydrochloride, Date of authorisation: 16/02/2022, Revision: 5, Status: Authorised
- Orphan designation: ixodes ricinus contact phase inhibitor Treatment of non-traumatic spontaneous intracerebral haemorrhage, 25/03/2025 Positive